Shionogi & Co., Ltd.
Supplementary Materials to Financial Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027
Supplementary consolidated financial materials for the second quarter of the fiscal year ending March 2027. Revenue was 350.4 hundred million yen (substantial increase YoY), operating income was 115.2 hundred million yen, and quarterly profit was 119.6 hundred million yen. Full-year forecast has been revised; EBITDA is expected to reach 174.6 hundred million yen. Profit growth was driven by strengthened global deployment, consolidation of Torii Pharmaceutical, and transfer of the edaravone business. The pipeline list and foreign exchange assumptions were also updated.
Key Figures
- Revenue: 3,504
- Operating Income: 1,152
- Quarterly Profit: 1,196
AI要約
Performance Overview
Shionogi & Co., Ltd. reported consolidated revenue of 350.4 hundred million yen, operating income of 115.2 hundred million yen, and quarterly profit of 119.6 hundred million yen for the second quarter of the fiscal year ending March 2027. The full-year forecast has been revised. The primary drivers of revenue expansion were strengthened global expansion, consolidation of Torii Pharmaceutical, and the transfer of the edaravone business. Indicators such as ROE and ROA also showed improving trends.
Business Segments and Cost Factors
Contributions were significant from domestic prescription pharmaceuticals, overseas subsidiaries/exports, and royalty income, with a particularly large increase in royalty income. Although amortization of product-related intangible assets increased, operating income expanded, offsetting increases associated with consolidation of Torii Pharmaceutical and the edaravone business transfer. The full-year forecast will continue to be revised as appropriate.
Revenue by Segment
Gross Margin Trend
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
